Reengineering Ponatinib to Minimize Cardiovascular Toxicity.
Anna P HnatiukArne A N BruyneelDhanir TailorMallesh PandralaArpit DheerajWenqi LiRicardo SerranoDries A M FeyenMichelle M VuPrashila AmatyaSaloni GuptaYusuke NakauchiIsabel MorgadoVolker WiebkingRonglih LiaoMatthew H PorteusRavindra MajetiSanjay V MalhotraMark MercolaPublished in: Cancer research (2022)
Newly developed ponatinib analogs retain antitumor efficacy but elicit significantly decreased cardiotoxicity, representing a therapeutic opportunity for safer CML treatment.